A descriptive epidemiological study in East Anglia has shown a 6% excess of prostate cancer registrations during 1991–2000 relative to expectations based on pre-1991 trends, coincident with an increase in prostate-specific antigen (PSA) testing (Pashayan et al, 2006). This evidence concerns the gene KLK3 and prostate cancer.